Literature DB >> 28273376

Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome.

S Aurich1,2, J C Simon1,2, R Treudler1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28273376     DOI： 10.1111/jdv.14202

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  3 in total

1.  Omalizumab as a Succesfull Therapy in Normocomplementemic Urticarial Vasculitis: A Series of Four Patients and Review of the Literature.

Authors:  Ece Nur Degirmentepe; Kubra Kızıltac; Pırıl Etikan; Ralfi Singer; Bachar Memet; Emek Kocaturk
Journal:  Ann Dermatol       Date:  2019-05-01       Impact factor: 1.444

2.  Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab.

Authors:  Marianne de Brito; Gisela Huebner; DedeeF Murrell; Peter Bullpitt; Karin Hartmann
Journal:  Clin Transl Allergy       Date:  2018-09-21       Impact factor: 5.871

3.  Real-World Experience on Omalizumab Treatment for Patients with Normocomplementemic Urticarial Vasculitis.

Authors:  Taoming Liu; Juan Bai; Shuni Ying; Sheng Li; Yunlei Pan; Deren Fang; Jianjun Qiao; Hong Fang
Journal:  J Asthma Allergy       Date:  2021-04-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.